International Ophthalmology

, Volume 31, Issue 4, pp 271–275 | Cite as

Effect of pan retinal photocoagulation on the serum levels of vascular endothelial growth factor in diabetic patients

  • Masoud Reza Manaviat
  • Maryam Rashidi
  • Mohammad Afkhami-Ardekani
  • Javad Mohiti-Ardekani
  • MariaEsther Bandala-Sanchez
Original Paper


This study tests the hypothesis that subjects with proliferative diabetic retinopathy (PDR) have a detectable rise in levels of serum vascular endothelial growth factor (VEGF), which is an important regulator of angiogenesis. Our investigation aims to evaluate plasma VEGF changes after pan-retinal photocoagulation (PRP) in diabetic patients. Twenty-nine type two diabetic patients (17 male, 12 female: mean age 53.13 ± 12.22 years) with PDR secondary to diabetes were studied. Blood samples were obtained before and at 2 months after the last PRP session. Serum VEGF levels were measured by ELISA. After PRP, the mean serum VEGF decreased, but this reduction was not remarkable (88.68 ± 71.09 vs. 77.01 ± 60.33 ng/ml) (P = 0.18). There was a statistically significant difference in serum VEGF changes between patients who had regressed PDR with patients who had progressed PDR (−25.98 ± 47.37 vs. 56.44 ± 31.7 ng/ml) (P = 0.003). Our results showed a significant reduction in levels of serum VEGF in the patients who had successful laser treatment. Our findings suggest that serum VEGF levels could be used for monitoring diabetic retinopathy outcome.


Type 2 diabetes Proliferative diabetic retinopathy Vascular endothelial growth factor Pan retinal photocoagulation 



This study was supported by Yazd diabetes Research Center of Shahid Sadoughi University of Medical Sciences. The authors wish to thank all the colleagues who supported the research, especially Laila Azod for assistance with sampling.


No competing financial interests exist.


  1. 1.
    Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF (1983) Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219(4587):983–985PubMedCrossRefGoogle Scholar
  2. 2.
    Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J et al (1989) Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246(4935):1309–1312PubMedCrossRefGoogle Scholar
  3. 3.
    Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A (1994) Glioblastoma growth is inhibited in vivo by a negative dominant Flk-1 mutant. Nature 367:576–579PubMedCrossRefGoogle Scholar
  4. 4.
    Cooper ME, Vranes D, Youssef S, Stacker SA, Cox AJ, Rizkalla B et al (1999) Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 48(11):2229–2239PubMedCrossRefGoogle Scholar
  5. 5.
    Aiello LP (1997) Clinical implications of vascular growth factors in proliferative retinopathies. Curr Opin Ophthalmol 8(3):19–31PubMedCrossRefGoogle Scholar
  6. 6.
    Funatsu H, Yamashita H, Noma H, Mochizuki H, Mimura T, Ikeda T et al (2003) Outcome of vitreous surgery and the balance between vascular endothelial growth factor and endostatin. Investig Ophthalmol Vis Sci 44(3):1042CrossRefGoogle Scholar
  7. 7.
    Chaturvedi N, Sjolie AK, Stephenson JM, Abrahamian H, Keipes M, Castellarin A (1998) Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 351(9095):28–31PubMedCrossRefGoogle Scholar
  8. 8.
    Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST et al (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331(22):1480–1487PubMedCrossRefGoogle Scholar
  9. 9.
    Lip GYH, Blann A (1997) von Willebrand factor: a marker of endothelial dysfunction in vascular disorders? Cardiovasc Res 34(2):255PubMedCrossRefGoogle Scholar
  10. 10.
    Lip PL, Belgore F, Blann AD, Hope-Ross MW, Gibson JM, Lip GYH (2000) Plasma VEGF and soluble VEGF receptor FLT-1 in proliferative retinopathy: relationship to endothelial dysfunction and laser treatment. Investig Ophthalmol Vis Sci 41(8):2115Google Scholar
  11. 11.
    Shinoda K, Ishida S, Kawashima S, Wakabayashi T, Matsuzaki T, Takayama M et al (1999) Comparison of the levels of hepatocyte growth factor and vascular endothelial growth factor in aqueous fluid and serum with grades of retinopathy in patients with diabetes mellitus. Br J Ophthalmol 83(7):834PubMedCrossRefGoogle Scholar
  12. 12.
    Manaviat MR, Afkhami M, Shoja MR (2004) Retinopathy and microalbuminuria in type II diabetic patients. BMC Ophthalmol 4:9PubMedCrossRefGoogle Scholar
  13. 13.
    Manaviat MR, Rashidi M, Afkhami-Ardekani M (2008) Four years incidence of diabetic retinopathy and effective factors on its progression in type II diabetes. Eur J Ophthalmol 18:1521–1522Google Scholar
  14. 14.
    Davis MD, Fisher MR, Gangnon RE, Barton F, Aiello LM, Chew EY et al (1998) Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: early treatment diabetic retinopathy study report #18. Invest Ophthalmol Vis Sci 39(2):233–252PubMedGoogle Scholar
  15. 15.
    Celebiler Cavusoglu A, Bilgili S, Alaluf A, Do an A, lmaz Y, Aslanca D et al (2007) Vascular endothelial growth factor level in the serum of diabetic patients with retinopathy. Ann Ophthalmol 39(3):205–208CrossRefGoogle Scholar
  16. 16.
    Ozturk BT, Bozkurt B, Kerimoglu H, Okka M, Kamis U, Gunduz K (2009) Effect of serum cytokines and VEGF levels on diabetic retinopathy and macular thickness. Mol Vis 15:1906–1914PubMedGoogle Scholar
  17. 17.
    Meleth AD, Agron E, Chan CC, Reed GF, Arora K, Byrnes G et al (2005) Serum inflammatory markers in diabetic retinopathy. Investig Ophthalmol Vis Sci 46(11):4295CrossRefGoogle Scholar
  18. 18.
    Kakizawa H, Itoh M, Itoh Y, Imamura S, Ishiwata Y, Matsumoto T et al (2004) The relationship between glycemic control and plasma vascular endothelial growth factor and endothelin-1 concentration in diabetic patients. Metabolism 53(5):550–555PubMedCrossRefGoogle Scholar
  19. 19.
    Webb NJA, Watson CJ, Roberts ISD, Bottomley MJ, Jones CA, Lewis MA et al (1999) Circulating vascular endothelial growth factor is not increased during relapses of steroid-sensitive nephrotic syndrome. Kidney Int 55(3):1063PubMedCrossRefGoogle Scholar
  20. 20.
    Zorena K, Myśliwska J, Myśliwiec M, Rybarczyk-Kapturska K, Malinowska E, Wiśniewski P, Raczyńska K (2010) Association between vascular endothelial growth factor and hypertension in children and adolescents type I diabetes mellitus. Hum Hypertens 24(11):755–762CrossRefGoogle Scholar
  21. 21.
    Emani S, Ramlawi B, Sodha NR, Li J, Bianchi C, Sellke FW (2009) Increased vascular permeability after cardiopulmonary bypass in patients with diabetes is associated with increased expression of vascular endothelial growth factor and hepatocyte growth factor. J Thorac Cardiovasc Surg 138(1):185–191PubMedCrossRefGoogle Scholar
  22. 22.
    Deguchi T, Hashiguchi T, Horinouchi S, Uto T, Oku H, Kimura K, Makisumi K, Arimura K (2009) Serum VEGF increases in diabetic polyneuropathy, particularly in the neurologically active symptomatic stage. Diabet Med 26(3):247–252PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2011

Authors and Affiliations

  • Masoud Reza Manaviat
    • 1
  • Maryam Rashidi
    • 2
  • Mohammad Afkhami-Ardekani
    • 3
  • Javad Mohiti-Ardekani
    • 4
  • MariaEsther Bandala-Sanchez
    • 5
  1. 1.Department of OphthalmologyShahid Sadougdi University of Medical Science, Yazd Diabetes Research CenterYazdIran
  2. 2.Yazd Diabetes Research CenterJomhoori BoulevardIran
  3. 3.Department of EndocrinologyYazd Diabetes Research CenterYazdIran
  4. 4.Department of BiochemistryShahid Sadougdi University of Medical Science, Diabetes Research CenterYazdIran
  5. 5.Walter & Eliza Hall Institute of Medical ResearchMelbourneAustralia

Personalised recommendations